Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

109.85
+0.79000.72%
Post-market: 109.01-0.8443-0.77%19:42 EDT
Volume:3.96M
Turnover:435.18M
Market Cap:136.65B
PE:23.22
High:110.72
Open:108.58
Low:108.57
Close:109.06
Loading ...

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-06-23

Reuters
·
23 Jun

Bernstein Remains a Buy on Gilead Sciences (GILD)

TIPRANKS
·
20 Jun

BUZZ-Street View: Gilead's HIV injection has multi-billion peak sales potential

Reuters
·
20 Jun

Wolfe Research Adjusts Price Target on Gilead Sciences to $135 From $115

MT Newswires Live
·
20 Jun

Citi views Yeztugo as ‘key growth driver’ for Gilead

TIPRANKS
·
20 Jun

South African Markets -Factors to watch on June 20

Reuters
·
20 Jun

Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges

TIPRANKS
·
19 Jun

Morgan Stanley says FDA approval of Yeztugo ‘an expected positive’ for Gilead

TIPRANKS
·
19 Jun

Mizuho says Gilead Yeztugo label looks clean

TIPRANKS
·
19 Jun

Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating

TIPRANKS
·
19 Jun

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires Live
·
19 Jun

Gilead Sciences Shares Rise in Volume Spike, Last up 0.5% at $108.48

THOMSON REUTERS
·
19 Jun

US FDA approves Gilead's twice-yearly injection for HIV prevention

Reuters
·
19 Jun

FDA: Gilead's Yeztugo Receives FDA Approval for Hiv Prevention

THOMSON REUTERS
·
19 Jun

Gilead receives FDA approval for HIV prevention injection

TIPRANKS
·
19 Jun

Wells Fargo Remains a Buy on Gilead Sciences (GILD)

TIPRANKS
·
19 Jun

Gilead Sciences' Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares

Reuters
·
18 Jun

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
18 Jun

Citi Sticks to Their Buy Rating for Gilead Sciences (GILD)

TIPRANKS
·
17 Jun

Trump Says Pharma Tariffs Coming Very Soon

Reuters
·
17 Jun